Diet plus infliximab for kids with Crohn’s
Part of Digestive system clinical trials.
This study tests if a special diet (called CDED) combined with infliximab (a biologic drug) is more effective than infliximab alone for children with newly diagnosed or relapsed moderate-to-severe Crohn’s disease. It aims to improve gut healing and reduce inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with Crohn’s disease within the last 12 months (or a flare-up within that time)
- Has moderate to severe inflammation in the small and/or large intestine, and is starting infliximab (Remicade)
- Has never taken a biologic medicine before
- Has evidence of active inflammation (e.g., high stool or blood markers)
- Is between the 5th and 95th weight-for-age percentile, and is not pregnant or breastfeeding
- No bowel surgery, no severe fistulas, no strictures, and no other gut diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This study tests whether adding a special diet (the Crohn's Disease Exclusion Diet) to standard anti-TNF medicine works better than the medicine alone for people with moderate to severe Crohn's disease or ulcerative colitis. You would be asked to follow a specific meal plan for several weeks while taking your regular medication.
This study tests whether a specific “exclusion diet” (removing certain foods) added to standard treatment can better control unstable Crohn’s disease in children. It may help reduce inflammation and flare-ups when symptoms are not controlled by usual medicines.
This study tests whether adding a special diet (called CDED) to a biologic medicine (infliximab or adalimumab) helps control Crohn's disease better than the medicine alone. It may reduce inflammation and improve symptoms.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This study tests whether combining infliximab (a biologic medicine that reduces inflammation) with azathioprine (an immune-suppressing drug) is safe and effective for children with moderate to severe Crohn's disease who haven't tried these medicines before.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.